BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 15642594)

  • 1. Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.
    Islam MS; Rahman SA; Mirzaei Z; Islam KB
    Life Sci; 2005 Jan; 76(11):1239-48. PubMed ID: 15642594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
    Deacon CF; Knudsen LB; Madsen K; Wiberg FC; Jacobsen O; Holst JJ
    Diabetologia; 1998 Mar; 41(3):271-8. PubMed ID: 9541166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion.
    Hui H; Yu R; Bousquet C; Perfetti R
    Endocrinology; 2002 Sep; 143(9):3529-39. PubMed ID: 12193567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
    Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
    Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic beta-cell lines for use in transplantation.
    Chepurny OG; Holz GG
    Cell Tissue Res; 2002 Feb; 307(2):191-201. PubMed ID: 11845326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.
    Burcelin R; Dolci W; Thorens B
    Metabolism; 1999 Feb; 48(2):252-8. PubMed ID: 10024091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene.
    Flamez D; Van Breusegem A; Scrocchi LA; Quartier E; Pipeleers D; Drucker DJ; Schuit F
    Diabetes; 1998 Apr; 47(4):646-52. PubMed ID: 9568699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
    Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells.
    Salapatek AM; MacDonald PE; Gaisano HY; Wheeler MB
    Mol Endocrinol; 1999 Aug; 13(8):1305-17. PubMed ID: 10446905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
    Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
    Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets.
    Siegel EG; Scharf G; Gallwitz B; Mentlein R; Morys-Wortmann C; Fölsch UR; Schmidt WE
    Eur J Clin Invest; 1999 Jul; 29(7):610-4. PubMed ID: 10411667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-induced regulation of glucagon-like peptide-I receptor function and expression in insulin-secreting beta cells.
    Fehmann HC; Jiang J; Pitt D; Schweinfurth J; Göke B
    Pancreas; 1996 Oct; 13(3):273-82. PubMed ID: 8884849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
    Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
    J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioactive GLP-1 in gut, receptor expression in pancreas, and insulin response to GLP-1 in diabetes-prone rats.
    Valverde I; Wang GS; Burghardt K; Kauri LM; Redondo A; Acitores A; Villanueva-Peñacarrillo ML; Courtois P; Sener A; Cancelas J; Malaisse WJ; Scott FW
    Endocrine; 2004 Feb; 23(1):77-84. PubMed ID: 15034199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of beta cell lines.
    Widmann C; Bürki E; Dolci W; Thorens B
    Mol Pharmacol; 1994 May; 45(5):1029-35. PubMed ID: 8190093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness.
    Montrose-Rafizadeh C; Wang Y; Janczewski AM; Henderson TE; Egan JM
    Mol Cell Endocrinol; 1997 Jun; 130(1-2):109-17. PubMed ID: 9220027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells.
    Moens K; Berger V; Ahn JM; Van Schravendijk C; Hruby VJ; Pipeleers D; Schuit F
    Diabetes; 2002 Mar; 51(3):669-75. PubMed ID: 11872665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1.
    Delmeire D; Flamez D; Hinke SA; Cali JJ; Pipeleers D; Schuit F
    Diabetologia; 2003 Oct; 46(10):1383-93. PubMed ID: 13680124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.